Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.

Slides:



Advertisements
Similar presentations
Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Advertisements

Dr. Chris Cobourn Medical Director and Surgeon Surgical Weight Loss Centre Staff Surgeon Trillium Health Centre Mississauga, Ontario.
Treatment Strategies for Diabetes and Obesity: Update 2013 Christopher Sorli, MD/PhD, FACE Chair, Department of Diabetes, Endocrinology and Metabolism.
Recovery of the β–cell function both in new and long-standing type 2 diabetic patients through long-term treatment with continuous subcutaneous insulin.
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.
Combination Therapy in Type 2 Diabetes
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association 2003.
LONG TERM BENEFITS OF ORAL AGENTS
Therapy of Type 2 Diabetes Mellitus: UPDATE
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Jaime Ponce MD, FACS, FASMBS Director of Bariatric Surgery Hamilton Medical Center Dalton Georgia USA LAGB Weight Loss and Diabetes 2010 Minimally Invasive.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Glycemic Control: When the Lower is Not the “Better”?
Diabetes Mellitus type II Optimizing Glucose Control Andrea Shaylor Lock Haven University PA Program February 26, 2009.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 3.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 1.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.
© 2013 Eli Lilly and Company Managing insulin therapy in Insulin resistance Speaker name and affiliation Prescribing information is available on the last.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 4 of 4.
Natural History of Type 2 Diabetes Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota. ObesityIFG*DiabetesUncontrolled Hyperglycemia.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
Lifestyle Modifications
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach Part 1 1.
Hippocrates Prize Prof A. Kokkinos (Greece).
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits.
Targets for Therapies/ New Guidelines
Type 1 Diabetes Mellitus
Macrovascular Complications Microvascular Complications
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
EFFICACY AND MECHANISM
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Strategies for the Practical Management of Type 2 Diabetes
Carbohydrate absorption inhibitors α-glucosidose inhibitors
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Pathophysiology and drug targets.
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa

Adapted from De Fronzo RA, Diabetes 2009 Increased Glucagon Secretion Neurotransmitter Dysfunction Decreased Incretin Effect Increased HGP Decreased Glucose Uptake Increased Glucose Reabsorption Increased Lipolysis Hyperglycemia Decreased Insulin Secretion Islet- cell 1.Effective treatment of type 2 diabetes requires multiple drugs used in combination to correct multiple pathophysiological defects 2.Treatment should be based on known pathogenic abnormalities and not simply on reduction of HbA1C 3.Therapy must be started early in the natural history of type 2 diabetes to prevent progressive beta-cell failure Therapeutic implications of the pathogenesis of type 2 diabetes

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM Glycemic targets - HbA1c < 7.0% (mean PG  mg/dl [ mmol/l ]) - Pre-prandial PG <130 mg/dl (7.2 mmol/l ) - Post-prandial PG <180 mg/dl (10.0 mmol/l ) - Individualization is key:  Tighter targets ( %) - younger, healthier  Looser targets ( % + ) - older, comorbidities, hypoglycemia prone, etc. - Avoidance of hypoglycemia PG = plasma glucose

Diabetes Care 2012, Diabetologia 2012 Therapeutic implications of the pathogenesis of type 2 diabetes Consider initial insulin therapy when A1c >10-12% Begin with these options if metformin contraindicated Consider initial dual combination therapy when A1c >9%

Diab Care, vol 32 n 11 November 2009 [..] For a chronic illness such as diabetes, it may be more accurate to use the term remission than cure. Current or potential future therapies for type 1 and type 2 diabetes will likely always leave patients at risk for relapse, given underlying pathophysiologic abnormalities and/or genetic predisposition The authors agreed upon the following definitions, which are the same for type 1 and type 2 diabetes: Remission is defined as achieving glycemia below the diabetic range in the absence of active pharmacologic (anti-hyperglycemic medications, immunosuppressive medications) or surgical (ongoing procedures such as repeated replacement of endoluminal devices) therapy

Buse JB et al. Diab Care 2009 HbA1c < 6.5% Glycemia mg/dl HbA1c < 6.0% Glycemia < 100 mg/dl

Mingrone G NEJM 2012 Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes 6.5

DIABETES REMISSION AFTER WEIGHT LOSS INTERVENTION Gregg EW JAMA 2012 Is it possible to have Remission of Type 2 Diabetes with Medical Therapy? Randomized control trial, 4 years follow-up 4503 pts

Retnakaran R, Zinman B, Diabetes, Obesity and Metabolism, Is it possible to have Remission of Type 2 Diabetes with Medical Therapy?

Chen A, Diabetes Care 2012 Is it possible to have Remission of Type 2 Diabetes with Medical Therapy? 118 pts in CSII for 2 wks, 53 non remission 65 in remission for >1year

Liu J End Jap % 60.6% 49.5% Is it possible to have Remission of Type 2 Diabetes with Medical Therapy?  -cell Function 188 patients

Liu J End Jap 2012 Is it possible to have Remission of Type 2 Diabetes with Medical Therapy?

Wen XU, Chin Med J 2009 Is it possible to have Remission of Type 2 Diabetes with Medical Therapy? 84 patients 42 patients

Weng J, Lancet 2008

Retnakaran R, Zinman B, Diabetes, Obesity and Metabolism, Predictors of successful sustained euglycemia Is it possible to have Remission of Type 2 Diabetes with Medical Therapy? When?

SUMMARY  The effects of medical treatment on diabetes are related to improvement or restoration of: a.insulin sensitivity (life style, weight loss);  -cell function (hormonal factors and reduction of glucotoxicity and lipotoxicity).  Rate of success of medical treatment in terms of diabetes remission may depend on the extent of  -cell dysfunction/loss at time of treatment and, hence, could be lower for: a.longer diabetes duration; b.less BMI.